BCTXZBriaCell Therapeutics Corp. Warrant
0.1050USDMkt Cap: —P/E: —3d ago
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.79M $
Revenue/Share—
Last Price0.1050 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.03
EPS (TTM)—
EPS (Forward)—
52W Range
0.10500% of range0.1731
52W High0.1731 USD
52W Low0.1050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE201.12%
ROA-81.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.13M $
CapEx (TTM)456.80K $
FCF Margin—
FCF Yield—
Net Debt-22.80M $
Net Debt/EBITDA0.71
Balance Sheet
Debt/Equity—
Current Ratio7.07
Quick Ratio6.35
Book Value/Sh3.318 USD
Cash/Share2.621 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float7.86M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta1.52
S&P 52W Chg19.18%
Avg Vol (30d)37.64K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—